Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1088856 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $92.95Day −1.32%Mkt cap $10.0BP/E (FY) 113.4×1Y +36.3%Off 52W high −4.8%Vol (1Y) 78.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,293 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.7% of sh out |
| Days to cover8.7d |
| 13F net flow (QoQ)+4.10% |
| Top-10 13F concentration62.6% |
| Next report (est.)2026-07-30 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)113.4× |
| Sales (TTM)$830.8M |
| Earnings (TTM)$55.2M |
| ROE15.0% |
| Net margin13.1% |
| ROIC8.3% |
| EPS growth 3Y−2.0% |
| Sales growth 3Y23.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+167.1% |
| 1Y+36.3% |
| 3Y+264.8% |
| 5Y+358.1% |
| 10Y+1502.6% |
| Since incept. (ann.)+14.0% |
Total return through 2026-07-29 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)78.6% |
| Ann. volatility (3Y)90.2% |
| Sharpe (1Y)0.86 |
| Sharpe (3Y)0.87 |
| Max drawdown (1Y)−64.4% |
| Max drawdown (3Y)−71.9% |
| Beta (3Y vs SPY)0.34 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 12.2M | $490M | 11.24% | +0.7% |
| INGALLS & SNYDER LLC | 7.6M | $307M | 7.04% | +5.7% |
| RENAISSANCE TECHNOLOGIES LLC | 5.7M | $229M | 5.26% | −1.3% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.8M | $194M | 4.46% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1M | $164M | 3.77% | new |
| Parallel Advisors, LLC | 4.0M | $160M | 3.68% | +2.5% |
| STATE STREET CORP | 3.2M | $129M | 2.96% | +7.2% |
| FMR LLC | 3.2M | $129M | 2.95% | +32.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-30 | −$0.30 | −276.5% | $164.9M | +4.9% |
| 2025-12-31 | 2026-02-24 | — | — | $202.1M | +11.1% |
| 2025-09-30 | 2025-11-04 | $0.16 | −61.0% | $207.6M | +13.7% |
| 2025-06-30 | 2025-07-31 | $0.29 | −9.4% | $194.4M | +18.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-07-30 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
